cluster headache - search results

If you're not happy with the results, please do another search

INS 2022: Occipital nerve stimulation shows clinical benefit and safety in chronic cluster headache

A randomised controlled trial (RCT) presented at the International Neuromodulation Society (INS) congress (21–26 May 2022, Barcelona, Spain) has demonstrated significant and clinically relevant...

Pulsante Therapy awarded prestigious Forfait Innovation package to fast-track medical innovation for cluster headache...

Autonomic Technologies has announced that the College of the French National Authority for Health (HAS) issued a favourable opinion on a Forfait Innovation package...

Pathway R-1 registry study demonstrates Pulsante therapy effectively treats cluster headaches

Autonomic Technologies, Inc., has announced the publication of results from the Pathway R-1 registry study demonstrating the Pulsante SPG Microstimulator System’s effectiveness in more...

NICE provides positive guidance on gammaCore treatment for the prevention and acute treatment of...

The UK’s National Institute of Health and Care Excellence (NICE) has published guidance that electroCore’s non-invasive vagus nerve stimulation treatment (gammaCore) for the prevention...

electroCore non-invasive vagus nerve stimulation is effective in treating cluster headaches

Seventy-nine per cent of patients who completed the trial (15 out of 19) reported an overall improvement in their condition.

Randomised data show gammaCore significantly reduces cluster headache attack frequency

A large scale randomised clinical trial of the gammaCore therapy in chronic cluster headache not only significantly reduced the number of cluster headache attacks beyond the best available standard of care, but patients also experienced a greater reduction in number of attacks the longer they stayed on treatment.

Trial shows gammaCore is effective in reducing cluster headaches

In a multicentre, randomised, trial across Europe, electroCore's non-invasive vagus nerve stimulation therapy was found to meet its primary endpoint of statistical significance in reducing the number of cluster headache attacks when compared with the standard of care.

Encouraging trial results for electroCore’s non-invasive vagus nerve stimulation treatment for headaches

In an open label trial, electroCore's handheld non-invasive vagus nerve stimulation device gammaCore, completely resolved 44.8% of migraines within 30 minutes, with an additional 11.4% experiencing moderate benefits (incomplete resolution of their headaches) by two hours.

NeuroNews’ top 10 most popular stories of June 2022

In-depth discussions regarding a “landmark” study in medium vessel occlusion (MeVO) stroke, and the first thrombectomy procedures with a novel balloon guide catheter device,...

Registration opens for 15th International Neuromodulation Society congress in Barcelona

At the International Neuromodulation Society (INS) 15th world congress (21–26 May 2022; Barcelona, Spain), researchers from over 40 countries will present plenary lectures and...

Cervical non-invasive vagus nerve stimulation effectively relieves pain in migraine sufferers

A recent meta-analysis demonstrated that cervical non-invasive vagus nerve stimulation (nVNS) is a safe and effective method for acute pain relief in migraine and...

Researchers discover new potential marker for migraine

Researchers may have discovered a new marker found in the blood for episodic migraine, according to a study published in the online issue of...

Focus on: Neuromodulation

Over the past decade, neuromodulation has grown into a wide and varied field with approvals for additional applications increasing every year. NeuroNews now speaks...

electroCore appoints Piper Jaffray to deal with growing interest from pharma

electroCore has appointed Piper Jaffray to assist in discussions with pharma companies who are interested in partnering on the commercialisation of its non-invasive vagus nerve (nVNS) stimulation therapy.

electroCore’s funding US$10 million oversubscribed by all parties

The final tranche of US$15 million of the US$40 million was optional but following discussions between the investors this was not only made compulsory but increased by US$10 million to a total of US$50 million.

Migraine symptoms improve with transcranial magnetic stimulation

Fayyaz Ahmed, consultant neurologist, Hull and East Yorkshire Hospitals NHS Trust, UK, speaks to NeuroNews about transcranial magnetic stimulation, the systems being studied and...

Ali R Rezai

“My clinical and research career has been focused on the clinical applications of deep brain stimulation and the understanding of the mechanisms of deep...

ElectroCore receives Australian and Colombian regulatory approval for GammaCore Vagal Nerve Stimulation Therapy

GammaCore therapy has been approved for commercial sale by the Therapeutic Goods Administration in Australia and the National Institute of Surveillance of Medicine and Foods in the Ministry of Health in Colombia. GammaCore's non-invasive, non-pharmaceutical, neuromodulation therapy is indicated for the acute and/or prophylactic treatment of primary headache.

Isil Saatci

Pedro Lylyk

michael chen

Michael Chen